8 completed, 5 recruiting, 2 active not recruiting, 2 unknown. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 8, Recruiting 5, Active not recruiting 2, Unknown 2, Suspended 1 |
Follow Dapagliflozin 10mg Tab: new trials by email Literature Review of Dapagliflozin 10mg Tab trials Research Report on Dapagliflozin 10mg Tab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) Placebo, Dapagliflozin 10mg Tab - Gestational Hypertension, Hypertension in Pregnancy | Phase 4 | Recruiting | University of Michigan | 200 | 2025-03-02 | 2026-03-04 |
| Cardiotoxicity in Breast Cancer Patients Dapagliflozin 10mg Tab - Breast Cancer | Phase 4 | Recruiting | Helwan University | 40 | 2024-09-10 | 2025-09-22 |
| Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury Dapagliflozin 10mg Tab - Acute Kidney Injury, Percutaneous Coronary Intervention | Phase 4 | Suspended | Albert Einstein Healthcare Network | 250 | 2024-09-01 | 2024-07-31 |
| The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes Dapagliflozin 10mg Tab, Metformin 1000 mg (ttd), Placebo - Obesity, Dapagliflozin Adverse Reaction | Phase 4 | Active not recruiting | Oman Ministry of Health | 150 | 2024-04-22 | 2025-03-26 |
| SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus Dapagliflozin 10mg Tab, Placebo 10mg Tab - Chronic Hepatitis B | Phase 4 | Recruiting | Chinese University of Hong Kong | 412 | 2024-03-26 | 2026-03-18 |
| Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients Dapagliflozin 10mg Tab, Placebo - Kidney Transplant; Complications, Vascular Diseases | Phase 4 | Recruiting | University of Colorado, Denver | 80 | 2024-02-01 | 2025-05-29 |
| The Fontan Dapagliflozin Pilot Study Dapagliflozin 10mg Tab - Heart Failure | Phase 4 | Completed | Johns Hopkins University | 29 | 2023-11-08 | 2026-07-22 |
| Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF) Dapagliflozin 10mg Tab - Acute Heart Failure | Phase 4 | Completed | Cairo University | 117 | 2023-08-01 | 2024-02-28 |
| Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation Dapagliflozin 10mg Tab - Chronic Kidney Diseases | Phase 4 | Recruiting | University of Erlangen-Nürnberg Medical School | 48 | 2023-07-28 | 2026-05-06 |
| Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? Dapagliflozin 10mg Tab, Placebo - Kidney Transplant; Complications, Kidney Transplant Failure | Phase 4 | Active not recruiting | Oslo University Hospital | 330 | 2023-05-02 | 2026-10-20 |
| Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients Dapagliflozin 10mg Tab, Placebo - Chronic Kidney Diseases, Bone Diseases, Metabolic | Phase 4 | Completed | Mansoura University | 100 | 2022-09-01 | 2024-11-08 |
| Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome Dapagliflozin 10mg Tab - Nephrotic Syndrome, Sodium-Glucose Transporter 2 Inhibitors | Phase 4 | Completed | Ain Shams University | 60 | 2022-08-01 | 2023-09-07 |
| Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE) Dapagliflozin 10mg Tab - Dapagliflozin Adverse Reaction, Efficacy | Phase 4 | Unknown | Monaldi Hospital | 50 | 2022-08-01 | 2023-02-08 |
| Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) Dapagliflozin 10mg Tab, Placebo - Nonalcoholic Fatty Liver Disease, Type 2 Diabetes | Phase 4 | Completed | Rehab Werida | 50 | 2022-05-01 | 2025-02-04 |
| Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients Dapagliflozin 10Mg Tab - End-stage Renal Disease | Phase 4 | Completed | University of Campinas, Brazil | 5 | 2022-04-25 | 2023-03-09 |
| Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety Dapagliflozin 10mg Tab, Lobeglitazone 0.5 mg, Dapagliflozin + Lobeglitazone - Diabetes Type 2 | Phase 4 | Unknown | Seoul National University Bundang Hospital | 99 | 2022-01-01 | 2023-08-14 |
| Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy Dapagliflozin 10mg Tab - Pancreatic Lipomatosis | Phase 4 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 50 | 2021-08-01 | 2023-04-10 |
| Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Dapagliflozin 10mg Tab, Placebo, Withings BPM Connect - Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | Phase 4 | Completed | University Medical Center Groningen | 20 | 2021-05-11 | 2024-04-22 |
Diabetes Mellitus (3) · Diabetes Mellitus, Type 2 (3) · Renal Insufficiency, Chronic (3) · Heart Failure (2) · Acute Kidney Injury (1) · Albuminuria (1) · Bone Diseases, Metabolic (1) · Breast Neoplasms (1) · Diabetes Complications (1) · Hepatitis B, Chronic (1) · Hypertension, Pregnancy-Induced (1) · Kidney Failure, Chronic (1) · Nephrotic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1)
Ain Shams University (1) · Albert Einstein Healthcare Network (1) · Cairo University (1) · Chinese University of Hong Kong (1) · Helwan University (1) · Johns Hopkins University (1) · Mansoura University (1) · Monaldi Hospital (1) · Oman Ministry of Health (1) · Oslo University Hospital (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Rehab Werida (1) · Seoul National University Bundang Hospital (1) · University Medical Center Groningen (1) · University of Campinas, Brazil (1)
Egypt (5) · United States (4) · Brazil (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Netherlands (1) · Norway (1) · Oman (1) · South Korea (1)
Amira B. Kassem, Lecturer (1) · Ari Cedars (1) · Ashley Hesson, MD, PhD (1) · Grace LH Wong, MD (1) · Magdy Abdelhamid, Professor (1) · Rehab H Werida, Ass Prof. (1) · Thuraiya Al Harthi, Masters (1) · Trond Geir Jenssen, MD (1) · Yasmin Essam, Bachlor (1)
PMID 23707905, PMID 26914659, PMID 37227937, PMID 38430085, PMID 42315275